<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Shock therapy delivery by implantable cardioverter-defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) can be painful and may have negative psychological consequences </plain></SENT>
<SENT sid="1" pm="."><plain>Reducing shock burden for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> and cardiac resynchronization therapy defibrillators (CRT-Ds) may have beneficial consequences </plain></SENT>
<SENT sid="2" pm="."><plain>This may be achieved by avoiding inappropriate shocks for <z:hpo ids='HP_0004755'>supraventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>) and by limiting appropriate shocks to only those that are necessary to convert <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: The programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock study (PROVIDE) is a prospective, randomized, multicentre study that will test the hypothesis that a combination of pre-selected ventricular tachyarrhythmia detection, anti-<z:hpo ids='HP_0001649'>tachycardia</z:hpo> pacing, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> discriminator parameters will prolong the time to first shock without increasing arrhythmic <z:hpo ids='HP_0001279'>syncope</z:hpo> in patients receiving <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> for primary prevention </plain></SENT>
<SENT sid="4" pm="."><plain>Patients receiving St Jude Medical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> and CRT-Ds for primary prevention will be randomized 1:1 to one of two <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> detection and therapy approaches </plain></SENT>
<SENT sid="5" pm="."><plain>The study will enroll and follow 1600 patients for at least 1 year or until 226 first shocks have been documented in the total study population </plain></SENT>
<SENT sid="6" pm="."><plain>The primary endpoint of the study is the mean time to first shock and the safety endpoint is the rate of arrhythmic <z:hpo ids='HP_0001279'>syncope</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: The PROVIDE trial is a randomized controlled study, designed to assess if a pre-selected combination of programming parameters can reduce shock burden among patients receiving <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>/CRT-Ds for primary prevention </plain></SENT>
</text></document>